Pharmascience Inc. Launches pms-FLUTICASONE PROPIONATE/SALMETEROL DPI for the Maintenance Treatment of Asthma and COPD
MONTREAL, March 18, 2020 -- (Healthcare Sales &Marketing Network) - Pharmascience Inc. is proud to bring to market a new product for the maintenance treatment of asthma and COPD. pms-FLUTICASONE PROPIONATE/SALMETEROL DPI, a generic alternative to ADVAIR ... Biopharmaceuticals, Generics, Drug Delivery, Product Launch Pharmascience, FLUTICASONE, SALMETEROL, ADVAIR DISKUS, COPD
Authors: Utley C, Gold MH, Hall M Abstract Background/Significance of problem: Atopic Dermatitis (AD) is a common, chronic, inflammatory dermatosis and skin disease that follows a relapsing pattern and requires a dynamic stepwise approach to management.Providers feel comfortable treating chronic disease states with a guided tool or care plan in many chronic diseases.Care plans used in many chronic diseases such as asthma, diabetes, and COPD have demonstrated effectiveness in disease and healthcare provider management.There is an unmet need for a universal AD care plan for providers. Clinical question/project purpos...
ConclusionsOut of e-prescriptions for inhaled medications issued in 2018 in Poland, 15.3% were not redeemed. The degree of primary non-adherence was influenced by age, but not gender. Significant differences between MDIs and DPIs and between inhalers with/without a dosage counter were observed.
AbstractThe coronavirus disease (COVID-19) is caused by Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and presents with respiratory symptoms which can be life threatening in severe cases. At the start of the pandemic, allergy, asthma, and chronic obstructive pulmonary disease (COPD) were considered as risk factors for COVID-19 as they tend to exacerbate during respiratory viral infections. Recent literature has not shown that airway allergic diseases is a high-risk factor or that it increases the severity of COVID-19. This is due to a decrease in Angiotensin-converting enzyme 2 (ACE2) gene expression in the ...
In this study, the effects of a novel pendrin inhibitor, YS-01, were investigated in an LPS-induced acute lung injury (ALI) mice model, and the mechanism underlying the effect of YS-01 was examined.Methods: Lipopolysaccharide (LPS, 10 mg/kg) was intranasally instilled in wild type (WT) and pendrin-null mice. YS-01 (10 mg/kg) was administered intra-peritoneally before or after LPS inhalation. Lung injury parameters were assessed in the lung tissue and bronchoalveolar lavage fluid (BALF). Pendrin levels in the BALF of 41 patients with acute respiratory distress syndrome (ARDS) due to pneumonia and 25 control (solitary pulmon...
CONCLUSION: Policies related to e-cigarettes need to be reevaluated and clearly communicated to improve prevention efforts for women of childbearing age. PMID: 33005962 [PubMed - in process]
This article presents the data about the clinical features of ACO, the current information regarding the underlying pathophysiology of the syndrome, and current understanding of therapeutic options.
Conditions: Cancer; COPD; Asthma; Bronchiectasis Adult; Interstitial Lung Disease; Cystic Fibrosis; Chronic Heart Failure; Sickle Cell Disease; Renal Failure; Liver Failure; Post COVID-19; Dyspnea Intervention: Other: SELF-BREATHE Sponsors: King's College Hospital NHS Trust; King's College London Not yet recruiting
ConclusionCXCR1/2 antagonist Ladarixin offers a new strategy for therapeutic treatment of acute and chronic neutrophilic airway inflammation, even in the context of corticosteroid-insensitivity.
Publication date: Available online 29 September 2020Source: Journal of Evidence Based Dental PracticeAuthor(s): Niamh Kelly, Ikhlas El Karim
This study supports the feasibility of machine learning applied to primary care data to screen for undiagnosed NTMLD patients, with results indicating that there may be a substantial number of undiagnosed cases of NTMLD in the UK.